Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Qatar LNG Ships U-Turn After Attempt to Pass Through Hormuz - 2What to know about King Charles III's cancer treatment and his message to the public
- 36 Eyewear Brands Worth Purchasing
- 4New ‘Cloud-9’ object could reveal the secrets of dark matter
- 5EU Commission slams Israel's death penalty law for Palestinians
- Several injured as man threatens attack on German high-speed train
- How AI fixed the James Webb Space Telescope's blurry vision
- Going with Children: Tips for Tranquil Family Get-aways
- Meet ‘NASA Mike,’ who’s done 105,000 handstands around the world
- Far-right leader Le Pen to attend Brigitte Bardot's funeral
- Make Your Fantasy Closet: 10 Immortal Design Fundamentals
- 'Outrageous and illegal' : UNRWA slams Israel for cutting off its water, comms and electric in Gaza
- Liste des pr\u00eats qui ne n\u00e9cessitent pas de remboursement
- German diesel hits new records over Easter weekend
